The primary endpoint was the percentage change in body weight from baseline to week 48, with secondary endpoints including the proportion of participants achieving clinically meaningful weight loss thresholds and changes in cardiometabolic risk markers
Promising effects beyond weight loss Researchers are currently studying the effect of GLP-1s on a wide range of conditions beyond diabetes, obesity, and heart disease, including renal, hepatic, neurological, and substance-use disorders
Confirm patient consent and understanding
Nutritional patterns can either enhance or hinder the medications effectscertain macronutrient compositions lead to better insulin response, digestion efficiency, and metabolic adaptations
Take the Next Step If youre ready to begin a medically supervised semaglutide program under the care of a board-certified plastic surgeon, contact Gupta Plastic Surgery today
doi: 10.1155/ije/2876156, 40